Loading clinical trials...
Loading clinical trials...
ACE Inhibitors or ARBs Discontinuation for Clinical Outcome Risk Reduction in Patients Hospitalized for the Endemic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection: the Randomized ACORES-2 Study
Conditions
Interventions
1: discontinuation of RAS blocker therapy
2: continuation of RAS blocker therapy
Locations
1
France
Cardiologie, Groupe Hospitalier Pitié-Salpêtrière
Paris, France
Start Date
April 9, 2020
Primary Completion Date
December 9, 2020
Completion Date
January 9, 2021
Last Updated
April 9, 2021
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions